Nikolett Nagy

Budapest, BU 1082, Hungary

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.

Journal: Cancer metastasis reviews
Published: December 10, 2025

Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Journal: Prostate cancer and prostatic diseases
Published: December 09, 2025

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Journal: Prostate cancer and prostatic diseases
Published: January 06, 2023

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Journal: Cancer medicine
Published: September 20, 2022

Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.

Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.

Journal: International journal of cancer
Published: December 15, 2021

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.

Journal: Journal of cellular and molecular medicine
Published: May 31, 2021

A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.

A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.

Journal: International journal of cancer
Published: April 28, 2021

Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer

Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer

Journal: Orvosi hetilap
Published: May 05, 2020

Prevalence of APC and PTEN Alterations in Urachal Cancer.

Prevalence of APC and PTEN Alterations in Urachal Cancer.

Journal: Pathology oncology research : POR
Published: March 02, 2020

Urachal Cancer: an update of current molecular findings

Urachal Cancer: an update of current molecular findings

Journal: Der Pathologe
Published: November 10, 2019

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Journal: International journal of cancer
Published: October 29, 2017
Showing 1-11 of 11

Last Updated: 09/26/2026